Home > Insider Trading > Filing (0001012975-16-001507)

Filing Details

Accession Number:: 0001012975-16-001507
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2016-09-26 16:03:34
Reporting Period:: 2016-09-22

Filing Date:: 2016-09-26
Accepted Time:: 2016-09-26 16:03:34
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1485003	Eleven Biotherapeutics Inc.	EBIO	()	4

Insiders

Cik	Name	Reported Address	Director	Officer	Large Shareholder	Other
1222012	Noubar Afeyan	1 Memorial Drive, 7Th Floor Cambridge MA 02142	No	No	Yes	No
1255927	Jr M Edwin Kania	1 Memorial Drive, 7Th Floor Cambridge MA 02142	No	No	Yes	No
1503559	Flagship Ventures Fund Iv, L.p.	1 Memorial Drive, 7Th Floor Cambridge MA 02142	No	No	Yes	No
1508051	Flagship Ventures Fund Iv General Partner Llc	1 Memorial Drive, 7Th Floor Cambridge MA 02142	No	No	Yes	No
1508052	Flagship Ventures Fund 2007, L.p.	1 Memorial Drive, 7Th Floor Cambridge MA 02142	No	No	Yes	No
1508053	Flagship Ventures 2007 General Partner Llc	1 Memorial Drive, 7Th Floor Cambridge MA 02142	No	No	Yes	No
1590973	Flagship Ventures Fund Iv-Rx, L.p.	1 Memorial Drive, 7Th Floor Cambridge MA 02142	No	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2016-09-22	112,731	$3.18	668,912	No	4	S	Direct
Common Stock	Disposition	2016-09-22	28,163	$3.18	167,288	No	4	S	Direct
Common Stock	Disposition	2016-09-22	188,367	$3.17	480,545	No	4	S	Direct
Common Stock	Disposition	2016-09-22	47,090	$3.17	120,198	No	4	S	Direct
Common Stock	Disposition	2016-09-23	12,482	$3.16	468,063	No	4	S	Direct
Common Stock	Disposition	2016-09-23	3,118	$3.16	117,080	No	4	S	Direct
Common Stock	Disposition	2016-09-23	41,178	$3.10	426,885	No	4	S	Direct
Common Stock	Disposition	2016-09-23	10,293	$3.10	106,787	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	1,833,802	Direct

Footnotes

Held by Flagship Ventures Fund IV, L.P. ("Flagship IV"). Flagship Ventures Fund IV General Partner LLC ("Flagship IV LLC") is the general partner of Flagship IV. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV. Each of the filing persons, other than Flagship IV, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Held by Flagship Ventures Fund IV-Rx, L.P. ("Flagship IV-Rx"). Flagship IV LLC is the general partner of Flagship IV Rx. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship IV LLC. Flagship IV LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship IV-Rx. Each of the filing persons, other than Flagship IV-Rx, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
Held by Flagship Ventures Fund 2007, L.P. ("Flagship 2007"). Flagship Ventures 2007 General Partner LLC ("Flagship 2007 LLC") is the general partner of Flagship 2007. Noubar B. Afeyan, Ph.D. and Edwin M. Kania, Jr. are the managers of Flagship 2007 LLC. Flagship 2007 LLC and each of these individuals may be deemed to share voting and investment power with respect to all shares held by Flagship 2007. Each of the filing persons, other than Flagship 2007, disclaims beneficial ownership of such shares except to the extent of his or its pecuniary interest therein.
The transactions were executed in multiple trades at prices ranging from $3.15 to $3.29. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
The transactions were executed in multiple trades at prices ranging from $3.15 to $3.235. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
The transactions were executed in multiple trades at prices ranging from $3.15 to $3.16. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.
The transactions were executed in multiple trades at prices ranging from $3.10 to $3.15. The price above reflects the weighted average sales price. Detailed information regarding the number of shares sold at each separate price will be provided upon request by the Commission staff, the Issuer or a security holder of the Issuer.